153 related articles for article (PubMed ID: 27191770)
1. Induced next-day somnolence in an elderly patient taking suvorexant concomitantly with diltiazem.
Shihyakugari A; Hori S; Miki A; Sawada Y
Int J Clin Pharmacol Ther; 2016 Aug; 54(8):645-8. PubMed ID: 27191770
[TBL] [Abstract][Full Text] [Related]
2. Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data.
Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
Psychopharmacology (Berl); 2017 Jun; 234(11):1703-1711. PubMed ID: 28265715
[TBL] [Abstract][Full Text] [Related]
3. Suvorexant for insomnia in patients with psychiatric disorder: A 1-week, open-label study.
Kishi T; Sakuma K; Okuya M; Ninomiya K; Oya K; Kubo M; Matsui Y; Nomura I; Okuyama Y; Matsunaga S; Iwata N
Neuropsychopharmacol Rep; 2019 Sep; 39(3):252-255. PubMed ID: 31283862
[TBL] [Abstract][Full Text] [Related]
4. Suvorexant-Induced Dream Enactment Behavior in Parkinson Disease: A Case Report.
Tabata H; Kuriyama A; Yamao F; Kitaguchi H; Shindo K
J Clin Sleep Med; 2017 May; 13(5):759-760. PubMed ID: 28212694
[TBL] [Abstract][Full Text] [Related]
5. Prompt improvement of difficulty with sleep initiation and waking up in the morning and daytime somnolence by combination therapy of suvorexant and ramelteon in delayed sleep-wake phase disorder: a case series of three patients.
Izuhara M; Kawano K; Otsuki K; Hashioka S; Inagaki M
Sleep Med; 2021 Apr; 80():100-104. PubMed ID: 33588260
[TBL] [Abstract][Full Text] [Related]
6. Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.
Wrishko RE; McCrea JB; Yee KL; Liu W; Panebianco D; Mangin E; Chakravarthy M; Martinez-Cantarin MP; Kraft WK
Clin Drug Investig; 2019 May; 39(5):441-451. PubMed ID: 30810914
[TBL] [Abstract][Full Text] [Related]
7. Suvorexant for the treatment of primary insomnia: A systematic review and meta-analysis.
Kuriyama A; Tabata H
Sleep Med Rev; 2017 Oct; 35():1-7. PubMed ID: 28365447
[TBL] [Abstract][Full Text] [Related]
8. Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials.
Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
Am J Geriatr Psychiatry; 2017 Jul; 25(7):791-802. PubMed ID: 28427826
[TBL] [Abstract][Full Text] [Related]
9. On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers.
Vermeeren A; Sun H; Vuurman EF; Jongen S; Van Leeuwen CJ; Van Oers AC; Palcza J; Li X; Laethem T; Heirman I; Bautmans A; Troyer MD; Wrishko R; McCrea J
Sleep; 2015 Nov; 38(11):1803-13. PubMed ID: 26039969
[TBL] [Abstract][Full Text] [Related]
10. Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects.
Uemura N; McCrea J; Sun H; Donikyan M; Zammit G; Liu R; Louridas B; Marsilio S; Lines C; Troyer MD; Wagner J
J Clin Pharmacol; 2015 Oct; 55(10):1093-100. PubMed ID: 25903940
[TBL] [Abstract][Full Text] [Related]
11. Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia.
Owen RT
Drugs Today (Barc); 2016 Jan; 52(1):29-40. PubMed ID: 26937493
[TBL] [Abstract][Full Text] [Related]
12. Suvorexant: scientifically interesting, utility uncertain.
Keks NA; Hope J; Keogh S
Australas Psychiatry; 2017 Dec; 25(6):622-624. PubMed ID: 28994603
[TBL] [Abstract][Full Text] [Related]
13. Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.
Kishi T; Matsunaga S; Iwata N
PLoS One; 2015; 10(8):e0136910. PubMed ID: 26317363
[TBL] [Abstract][Full Text] [Related]
14. Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials.
Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
J Clin Sleep Med; 2016 Sep; 12(9):1215-25. PubMed ID: 27397664
[TBL] [Abstract][Full Text] [Related]
15. Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia.
Patel KV; Aspesi AV; Evoy KE
Ann Pharmacother; 2015 Apr; 49(4):477-83. PubMed ID: 25667197
[TBL] [Abstract][Full Text] [Related]
16. Suvorexant approved for insomnia.
Traynor K
Am J Health Syst Pharm; 2014 Sep; 71(18):1524. PubMed ID: 25174007
[No Abstract] [Full Text] [Related]
17. Effects of Bedtime Dosing With Suvorexant and Zolpidem on Balance and Psychomotor Performance in Healthy Elderly Participants During the Night and in the Morning.
Bland H; Li X; Mangin E; Yee KL; Lines C; Herring WJ; Gillespie G
J Clin Psychopharmacol; 2021 Jul-Aug 01; 41(4):414-420. PubMed ID: 34181362
[TBL] [Abstract][Full Text] [Related]
18. Non-GABA sleep medications, suvorexant as risk factors for falls: Case-control and case-crossover study.
Ishibashi Y; Nishitani R; Shimura A; Takeuchi A; Touko M; Kato T; Chiba S; Ashidate K; Ishiwata N; Ichijo T; Sasabe M
PLoS One; 2020; 15(9):e0238723. PubMed ID: 32916693
[TBL] [Abstract][Full Text] [Related]
19. Safety profile and clinical course of patients with insomnia administered suvorexant by initial treatment status in a post-marketing survey.
Sano H; Asai Y; Miyazaki M; Iwakura M; Maeda Y; Hara M
Expert Opin Drug Saf; 2019 Nov; 18(11):1109-1118. PubMed ID: 31478753
[No Abstract] [Full Text] [Related]
20. Suvorexant (Belsomra
Asai Y; Sano H; Miyazaki M; Iwakura M; Maeda Y; Hara M
Drugs R D; 2019 Mar; 19(1):27-46. PubMed ID: 30552562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
